<SEC-DOCUMENT>0001209191-23-004258.txt : 20230120
<SEC-HEADER>0001209191-23-004258.hdr.sgml : 20230120
<ACCEPTANCE-DATETIME>20230120162902
ACCESSION NUMBER:		0001209191-23-004258
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230119
FILED AS OF DATE:		20230120
DATE AS OF CHANGE:		20230120

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Deignan Charles A.
		CENTRAL INDEX KEY:			0001664690

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37783
		FILM NUMBER:		23541376

	MAIL ADDRESS:	
		STREET 1:		C/O CLEARSIDE BIOMEDICAL, INC.
		STREET 2:		1220 OLD ALPHARETTA ROAD, SUITE 300
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Clearside Biomedical, Inc.
		CENTRAL INDEX KEY:			0001539029
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				452437375
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		900 NORTH POINT PARKWAY
		STREET 2:		SUITE 200
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005
		BUSINESS PHONE:		678-270-3631

	MAIL ADDRESS:	
		STREET 1:		900 NORTH POINT PARKWAY
		STREET 2:		SUITE 200
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30005
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-01-19</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001539029</issuerCik>
        <issuerName>Clearside Biomedical, Inc.</issuerName>
        <issuerTradingSymbol>CLSD</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001664690</rptOwnerCik>
            <rptOwnerName>Deignan Charles A.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CLEARSIDE BIOMEDICAL, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>900 NORTH POINT PARKWAY, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>ALPHARETTA</rptOwnerCity>
            <rptOwnerState>GA</rptOwnerState>
            <rptOwnerZipCode>30005</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Financial Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-01-19</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>14030</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>1.50</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>363472</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a &quot;sell to cover&quot; transaction pursuant to a Rule 10b5-1 trading plan.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.59 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Mark Ballantyne, Attorney-in-Fact</signatureName>
        <signatureDate>2023-01-20</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
